Collegium PharmaceuticalCOLL
COLL
About: Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Employees: 357
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
235% more call options, than puts
Call options by funds: $617K | Put options by funds: $184K
23% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 26
1.4% more ownership
Funds ownership: 115.16% [Q4 2024] → 116.56% (+1.4%) [Q1 2025]
3% more capital invested
Capital invested by funds: $1.06B [Q4 2024] → $1.1B (+$30.9M) [Q1 2025]
0% more funds holding
Funds holding: 238 [Q4 2024] → 239 (+1) [Q1 2025]
22% less repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 97
100% less funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$37
14%
upside
Avg. target
$37
14%
upside
High target
$37
14%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Piper Sandler David Amsellem | 14%upside $37 | Neutral Reiterated | 9 May 2025 |
Financial journalist opinion
Based on 3 articles about COLL published over the past 30 days
Positive
MarketBeat
1 day ago
5 Hot Stocks With Summer Buybacks You Can Cash In On
Stock buybacks remain one of the most effective tools for boosting share prices, especially when backed by solid fundamentals. When a company is healthy, repurchasing shares reduces the float, enhances earnings per share, and signals confidence to the market.
Neutral
GlobeNewsWire
4 days ago
Collegium Announces $150 Million Share Repurchase Program
STOUGHTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced its Board of Directors has authorized a new share repurchase program to repurchase up to $150 million in common stock through December 31, 2026.
Positive
Seeking Alpha
1 week ago
Collegium Pharmaceutical: Stock Deserves A "Buy" Call On Undervaluation Of ADHD Drug
Collegium is shifting focus from opioids to ADHD with Jornay PM, which is showing strong prescription growth and could become a blockbuster product. The company is undervalued relative to peers, with potential for significant upside if Jornay PM delivers on revenue expectations and offsets future patent expirations. Management is strategically reducing debt and maintaining profitability, positioning Collegium for growth and potential shareholder returns through buybacks.
Neutral
GlobeNewsWire
1 month ago
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:
Neutral
GlobeNewsWire
1 month ago
Collegium Announces $25 Million Accelerated Share Repurchase Program
STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company's common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in January 2024. Upon completion of this ASR, Collegium will have $65 million remaining under the program.
Neutral
Seeking Alpha
2 months ago
Collegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call Transcript
Call Start: 16:30 January 1, 0000 5:05 PM ET Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q1 2025 Earnings Call May 8, 2025 16:30 ET Company Participants Ian Karp - Head, Investor Relations Vikram Karnani - President and Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants Les Sulewski - Truist Securities Serge Belanger - Needham & Co David Amsellem - Piper Sandler Operator Greetings and welcome to the Collegium Pharmaceutical First Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded.
Positive
Zacks Investment Research
2 months ago
Compared to Estimates, Collegium Pharmaceutical (COLL) Q1 Earnings: A Look at Key Metrics
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Positive
Zacks Investment Research
2 months ago
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.49 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.45 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
– Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM ® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1'25 with Cash, Cash Equivalents and Marketable Securities of $197.8 Million – – Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2025 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass.
Positive
Zacks Investment Research
2 months ago
Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy?
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charts implemented using Lightweight Charts™